High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam
Abnormalities in brain gamma-aminobutyric acid (GABA) and glutamate may be relevant to the underlying pathophysiology of anxiety disorders including social anxiety disorder (SAD). We used proton magnetic resonance spectroscopy (pMRS) to examine whole brain and regional GABA, glutamate and glutamine...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 2008-04, Vol.32 (3), p.739-743 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 743 |
|---|---|
| container_issue | 3 |
| container_start_page | 739 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 32 |
| creator | Pollack, Mark H. Jensen, J. Eric Simon, Naomi M. Kaufman, Rebecca E. Renshaw, Perry F. |
| description | Abnormalities in brain gamma-aminobutyric acid (GABA) and glutamate may be relevant to the underlying pathophysiology of anxiety disorders including social anxiety disorder (SAD).
We used proton magnetic resonance spectroscopy (pMRS) to examine whole brain and regional GABA, glutamate and glutamine in patients (
N
=
10) with SAD at baseline compared to a matched group of healthy controls (HC), and changes following 8 weeks of pharmacotherapy with levetiracetam.
For SAD subjects, there were significantly higher whole brain levels of glutamate and glutamine, though no significant differences in GABA. In the thalamus, glutamine was higher and GABA lower for SAD subjects. There was a significant reduction in thalamic glutamine with levetiracetam treatment.
Our findings provide preliminary support for impaired GABAergic and overactive glutamatergic function in social anxiety disorder and the potential relevance of changes in these systems for the anxiolytic response to levetiracetam. |
| doi_str_mv | 10.1016/j.pnpbp.2007.11.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70368435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0278584607004137</els_id><sourcerecordid>19512790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-58044e0233ffc4c750bbe05892fb2b956ea08bc439121547a82e1adf389d06a23</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi1ERZeFX4CEfIETG8YfSRwkDksFbaUipAJny7EnrVf5wnYKy68n243gRk8ej5559c68hLxgkDFgxdtdNvZjPWYcoMwYy4CLR2TFVKk2krPiMVkBn-tcyeKUPI1xBwBMgHhCTpniUHBVrMjvC39zu2k8to5-vv5KY5rcng4NPd9-2L6hN-2UTGcSUtO75ed7pL6ncbDetHP_l8e0p87HITgM7-g1xnHoI9I00BTQpA77RH_6dEtbvMPkg7E46zwjJ41pIz5f3jX5_unjt7OLzdWX88uz7dXGSqbS7B-kxHk50TRW2jKHukbIVcWbmtdVXqABVVspKsZZLkujODLjGqEqB4XhYk1eH3XHMPyYMCbd-WixbU2PwxR1CaJQUuQPgqzKGS8rmEFxBG0YYgzY6DH4zoS9ZqAP2eidvs9GH7LRjOmD_TV5uchPdYfu38wSxgy8WgATrWmbYHrr41-OA1NCyWrm3h85nK925zHoaD32Fp0PaJN2g_-vkT_Vsa4n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19512790</pqid></control><display><type>article</type><title>High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Pollack, Mark H. ; Jensen, J. Eric ; Simon, Naomi M. ; Kaufman, Rebecca E. ; Renshaw, Perry F.</creator><creatorcontrib>Pollack, Mark H. ; Jensen, J. Eric ; Simon, Naomi M. ; Kaufman, Rebecca E. ; Renshaw, Perry F.</creatorcontrib><description>Abnormalities in brain gamma-aminobutyric acid (GABA) and glutamate may be relevant to the underlying pathophysiology of anxiety disorders including social anxiety disorder (SAD).
We used proton magnetic resonance spectroscopy (pMRS) to examine whole brain and regional GABA, glutamate and glutamine in patients (
N
=
10) with SAD at baseline compared to a matched group of healthy controls (HC), and changes following 8 weeks of pharmacotherapy with levetiracetam.
For SAD subjects, there were significantly higher whole brain levels of glutamate and glutamine, though no significant differences in GABA. In the thalamus, glutamine was higher and GABA lower for SAD subjects. There was a significant reduction in thalamic glutamine with levetiracetam treatment.
Our findings provide preliminary support for impaired GABAergic and overactive glutamatergic function in social anxiety disorder and the potential relevance of changes in these systems for the anxiolytic response to levetiracetam.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2007.11.023</identifier><identifier>PMID: 18206286</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Anxiety Disorders - diagnosis ; Anxiety Disorders - drug therapy ; Anxiety Disorders - metabolism ; Anxiety disorders. Neuroses ; Biological and medical sciences ; Female ; GABA ; gamma-Aminobutyric Acid - metabolism ; Glutamate ; Glutamic Acid - metabolism ; Glutamine - metabolism ; Humans ; Levetiracetam ; Magnetic Resonance Spectroscopy ; Male ; Medical sciences ; Middle Aged ; MRS ; Neuropharmacology ; Nootropic Agents - therapeutic use ; Pharmacology. Drug treatments ; Phobia ; Piracetam - analogs & derivatives ; Piracetam - therapeutic use ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Social anxiety</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2008-04, Vol.32 (3), p.739-743</ispartof><rights>2007 Elsevier Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-58044e0233ffc4c750bbe05892fb2b956ea08bc439121547a82e1adf389d06a23</citedby><cites>FETCH-LOGICAL-c418t-58044e0233ffc4c750bbe05892fb2b956ea08bc439121547a82e1adf389d06a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pnpbp.2007.11.023$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20183849$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18206286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pollack, Mark H.</creatorcontrib><creatorcontrib>Jensen, J. Eric</creatorcontrib><creatorcontrib>Simon, Naomi M.</creatorcontrib><creatorcontrib>Kaufman, Rebecca E.</creatorcontrib><creatorcontrib>Renshaw, Perry F.</creatorcontrib><title>High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Abnormalities in brain gamma-aminobutyric acid (GABA) and glutamate may be relevant to the underlying pathophysiology of anxiety disorders including social anxiety disorder (SAD).
We used proton magnetic resonance spectroscopy (pMRS) to examine whole brain and regional GABA, glutamate and glutamine in patients (
N
=
10) with SAD at baseline compared to a matched group of healthy controls (HC), and changes following 8 weeks of pharmacotherapy with levetiracetam.
For SAD subjects, there were significantly higher whole brain levels of glutamate and glutamine, though no significant differences in GABA. In the thalamus, glutamine was higher and GABA lower for SAD subjects. There was a significant reduction in thalamic glutamine with levetiracetam treatment.
Our findings provide preliminary support for impaired GABAergic and overactive glutamatergic function in social anxiety disorder and the potential relevance of changes in these systems for the anxiolytic response to levetiracetam.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Anxiety Disorders - diagnosis</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Anxiety Disorders - metabolism</subject><subject>Anxiety disorders. Neuroses</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>GABA</subject><subject>gamma-Aminobutyric Acid - metabolism</subject><subject>Glutamate</subject><subject>Glutamic Acid - metabolism</subject><subject>Glutamine - metabolism</subject><subject>Humans</subject><subject>Levetiracetam</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MRS</subject><subject>Neuropharmacology</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Phobia</subject><subject>Piracetam - analogs & derivatives</subject><subject>Piracetam - therapeutic use</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Social anxiety</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi1ERZeFX4CEfIETG8YfSRwkDksFbaUipAJny7EnrVf5wnYKy68n243gRk8ej5559c68hLxgkDFgxdtdNvZjPWYcoMwYy4CLR2TFVKk2krPiMVkBn-tcyeKUPI1xBwBMgHhCTpniUHBVrMjvC39zu2k8to5-vv5KY5rcng4NPd9-2L6hN-2UTGcSUtO75ed7pL6ncbDetHP_l8e0p87HITgM7-g1xnHoI9I00BTQpA77RH_6dEtbvMPkg7E46zwjJ41pIz5f3jX5_unjt7OLzdWX88uz7dXGSqbS7B-kxHk50TRW2jKHukbIVcWbmtdVXqABVVspKsZZLkujODLjGqEqB4XhYk1eH3XHMPyYMCbd-WixbU2PwxR1CaJQUuQPgqzKGS8rmEFxBG0YYgzY6DH4zoS9ZqAP2eidvs9GH7LRjOmD_TV5uchPdYfu38wSxgy8WgATrWmbYHrr41-OA1NCyWrm3h85nK925zHoaD32Fp0PaJN2g_-vkT_Vsa4n</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Pollack, Mark H.</creator><creator>Jensen, J. Eric</creator><creator>Simon, Naomi M.</creator><creator>Kaufman, Rebecca E.</creator><creator>Renshaw, Perry F.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam</title><author>Pollack, Mark H. ; Jensen, J. Eric ; Simon, Naomi M. ; Kaufman, Rebecca E. ; Renshaw, Perry F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-58044e0233ffc4c750bbe05892fb2b956ea08bc439121547a82e1adf389d06a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Anxiety Disorders - diagnosis</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Anxiety Disorders - metabolism</topic><topic>Anxiety disorders. Neuroses</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>GABA</topic><topic>gamma-Aminobutyric Acid - metabolism</topic><topic>Glutamate</topic><topic>Glutamic Acid - metabolism</topic><topic>Glutamine - metabolism</topic><topic>Humans</topic><topic>Levetiracetam</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MRS</topic><topic>Neuropharmacology</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Phobia</topic><topic>Piracetam - analogs & derivatives</topic><topic>Piracetam - therapeutic use</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Social anxiety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pollack, Mark H.</creatorcontrib><creatorcontrib>Jensen, J. Eric</creatorcontrib><creatorcontrib>Simon, Naomi M.</creatorcontrib><creatorcontrib>Kaufman, Rebecca E.</creatorcontrib><creatorcontrib>Renshaw, Perry F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pollack, Mark H.</au><au>Jensen, J. Eric</au><au>Simon, Naomi M.</au><au>Kaufman, Rebecca E.</au><au>Renshaw, Perry F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>32</volume><issue>3</issue><spage>739</spage><epage>743</epage><pages>739-743</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Abnormalities in brain gamma-aminobutyric acid (GABA) and glutamate may be relevant to the underlying pathophysiology of anxiety disorders including social anxiety disorder (SAD).
We used proton magnetic resonance spectroscopy (pMRS) to examine whole brain and regional GABA, glutamate and glutamine in patients (
N
=
10) with SAD at baseline compared to a matched group of healthy controls (HC), and changes following 8 weeks of pharmacotherapy with levetiracetam.
For SAD subjects, there were significantly higher whole brain levels of glutamate and glutamine, though no significant differences in GABA. In the thalamus, glutamine was higher and GABA lower for SAD subjects. There was a significant reduction in thalamic glutamine with levetiracetam treatment.
Our findings provide preliminary support for impaired GABAergic and overactive glutamatergic function in social anxiety disorder and the potential relevance of changes in these systems for the anxiolytic response to levetiracetam.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>18206286</pmid><doi>10.1016/j.pnpbp.2007.11.023</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2008-04, Vol.32 (3), p.739-743 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70368435 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adolescent Adult Adult and adolescent clinical studies Aged Anxiety Disorders - diagnosis Anxiety Disorders - drug therapy Anxiety Disorders - metabolism Anxiety disorders. Neuroses Biological and medical sciences Female GABA gamma-Aminobutyric Acid - metabolism Glutamate Glutamic Acid - metabolism Glutamine - metabolism Humans Levetiracetam Magnetic Resonance Spectroscopy Male Medical sciences Middle Aged MRS Neuropharmacology Nootropic Agents - therapeutic use Pharmacology. Drug treatments Phobia Piracetam - analogs & derivatives Piracetam - therapeutic use Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Social anxiety |
| title | High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A38%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-field%20MRS%20study%20of%20GABA,%20glutamate%20and%20glutamine%20in%20social%20anxiety%20disorder:%20Response%20to%20treatment%20with%20levetiracetam&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Pollack,%20Mark%20H.&rft.date=2008-04-01&rft.volume=32&rft.issue=3&rft.spage=739&rft.epage=743&rft.pages=739-743&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/j.pnpbp.2007.11.023&rft_dat=%3Cproquest_cross%3E19512790%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19512790&rft_id=info:pmid/18206286&rft_els_id=S0278584607004137&rfr_iscdi=true |